Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).

Publikation

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).

Wissenschaftlicher Artikel/Review - 08.02.2023

Gillessen Silke, Procopio Giuseppe, Hayoz Stefanie, Kremer Eloïse, Schwitter Michael, Caffo Orazio, Lorente David, Pedrazzini Augusto, Roubaud Guilhem, Nenan Soazig, Omlin Aurelius, Buttigliero Consuelo, Delgado Mingorance Juan Ignacio, González-Del-Alba Aránzazu, Delgado Maria Teresa, Nolè Franco, Turco Fabio, Mestre Ricardo Pereira, Ribi Karin, Cathomas Richard

Zitation

Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, Lorente D, Pedrazzini A, Roubaud G, Nenan S, Omlin A, Buttigliero C, Delgado Mingorance J, González-Del-Alba A, Delgado M, Nolè F, Turco F, Mestre R, Ribi K, Cathomas R. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). J Clin Oncol 2023; 41:3608-3615.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

J Clin Oncol 2023; 41

Veröffentlichungsdatum

08.02.2023

eISSN (Online)

1527-7755

Seiten

3608-3615

Kurzbeschreibung/Zielsetzung

To assess the efficacy and safety of darolutamide maintenance after successful taxane chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).